SIMCor. Deliverable 9.6 - Devices approval experience report (BIO, M39)

This report provides an overview of the regulatory dossier (Pre-Submission) that BIOTRONIK submitted to the United States Food and Drug Administration (FDA) to gather feedback on the design of in-silico-clinical-trials for the US regulatory approval of the proprietary PAPS device. To provide insight for both the in-silico community and the specific development aspects of the PAPS device, a set of specific questions were submitted to the FDA. This experience report aims to provide direction for future FDA Pre-Submissions in the field of device-related in-silico-methods and is intended to guide first-time applicants and the in-silico-community. As the value of the FDA’s response is strongly connected to the quality of the questions, this report focuses on the process of identification and refinement of suitable and relevant questions. This report also suggests future strategies to increase the impact of in-silico methods to medical device development, including all endpoints to be covered in an in-silico-clinical trial.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-10-24
DOI
https://doi.org/10.5281/zenodo.13987334
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SIMCor. Deliverable 9.6 - Devices approval experience report (BIO, M39)

Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

SIMCor. Deliverable 9.6 - Devices approval experience report (BIO, M39)

article en

Abstract

This report provides an overview of the regulatory dossier (Pre-Submission) that BIOTRONIK submitted to the United States Food and Drug Administration (FDA) to gather feedback on the design of in-silico-clinical-trials for the US regulatory approval of the proprietary PAPS device. To provide insight for both the in-silico community and the specific development aspects of the PAPS device, a set of specific questions were submitted to the FDA. This experience report aims to provide direction for future FDA Pre-Submissions in the field of device-related in-silico-methods and is intended to guide first-time applicants and the in-silico-community. As the value of the FDA’s response is strongly connected to the quality of the questions, this report focuses on the process of identification and refinement of suitable and relevant questions. This report also suggests future strategies to increase the impact of in-silico methods to medical device development, including all endpoints to be covered in an in-silico-clinical trial.

Zenodo (CERN European Organization for Nuclear Research)
Biotronik (Germany) (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 63%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

SIMCor. Deliverable 9.6 - Devices approval experience report (BIO, M39) · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS